Effect of taurine on leucocyte functionLEI WANG; NA ZHAO; FANG ZHANG et al.European journal of pharmacology. 2009, Vol 616, Num 1-3, pp 275-280, issn 0014-2999, 6 p.Article

DNA guanine-guanine crosslinking sequence specificity of isophosphoramide mustard, the alkylating metabolite of the clinical antitumor agent ifosfamideSTRUCK, R. F; DAVIS, R. L; BERARDINI, M. D et al.Cancer chemotherapy and pharmacology. 2000, Vol 45, Num 1, pp 59-62, issn 0344-5704Article

Quality control and stability study using HPTLC : applications to cyclophosphamide in various pharmaceutical productsBOULIGAND, Jérome; STORME, Thomas; LAVILLE, Isabelle et al.Journal of pharmaceutical and biomedical analysis. 2005, Vol 38, Num 1, pp 180-185, issn 0731-7085, 6 p.Article

Diastereoselective addition of 2H-2-oxo-1,4,2-oxazaphosphinanes to aldehydes and iminesPIRAT, Jean-Luc; MONBRUN, Jérome; VIRIEUX, David et al.Journal of organic chemistry. 2005, Vol 70, Num 18, pp 7035-7041, issn 0022-3263, 7 p.Article

Comments on a biochemical model of cyclophosphamide hematotoxicityPORTIER, Christopher J; PARHAM, Frederick M.Journal of toxicology and environmental health. 2000, Vol 61, Num 5-6, pp 525-528, issn 0098-4108Conference Paper

Synthesis of I-aldofosfamide-perhydrothiazinesZIMMERMANN, Jürgen; BAUER, Hans-Herwig; HOHORST, Hans-Jürgen et al.Arzneimittel-Forschung. 2000, Vol 50, Num 9, pp 843-847, issn 0004-4172Article

Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamideFLOWERS, J. L; LUDEMAN, S. M; GAMESIK, M. P et al.Cancer chemotherapy and pharmacology. 2000, Vol 45, Num 4, pp 335-344, issn 0344-5704Article

Long term renal toxicity of ifosfamide in adult patients ― 5 year dataFARRY, James K; FLOMBAUM, Carlos D; LATCHA, Sheron et al.European journal of cancer (1990). 2012, Vol 48, Num 9, pp 1326-1331, issn 0959-8049, 6 p.Article

Diastereoselective Michael addition of 2H-2-oxo-1,4,2-oxaza phosphinanes to olefinsMONBRUN, Jérôme; DAYDE, Bénédicte; CRISTAU, Henri-Jean et al.Tetrahedron (Oxford. Print). 2011, Vol 67, Num 2, issn 0040-4020, 283, 540-545 [7 p.]Article

Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapyCHINNASWAMY, Girish; ERRINGTON, Julie; FOOT, Annabel et al.European journal of cancer (1990). 2011, Vol 47, Num 10, pp 1556-1563, issn 0959-8049, 8 p.Article

Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to CyclophosphamideMOSCHELLA, Federica; VALENTINI, Mara; ARICO, Eleonora et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 10, pp 3528-3539, issn 0008-5472, 12 p.Article

Conjunctival lymphoma following treatment with cyclophosphamideLORIDON, N. J. S; SIVERIO, C; CUNNINGHAM, E. T et al.Eye (London. 1987). 2010, Vol 24, Num 7, pp 1294-1295, issn 0950-222X, 2 p.Article

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organsNAKAHARA, Takeshi; UCHI, Hiroshi; LESOKHIN, Alexander M et al.Blood. 2010, Vol 115, Num 22, pp 4384-4392, issn 0006-4971, 9 p.Article

Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and AxitinibJIE MA; WAXMAN, David J.Clinical cancer research (Print). 2009, Vol 15, Num 2, pp 578-588, issn 1078-0432, 11 p.Article

Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in ChildrenOBERLIN, Odile; FAWAZ, Oumaya; RUBIE, Hervé et al.Journal of clinical oncology. 2009, Vol 27, Num 32, pp 5350-5355, issn 0732-183X, 6 p.Article

Personalized Dosing of Cyclophosphamide in theTotal Body Irradiation-Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic MalignancyMCCUNE, J. S; BATCHELDER, A; GUTHRIE, K. A et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 6, pp 615-622, issn 0009-9236, 8 p.Article

Design of new oxazaphosphorine anticancer drugsJUN LIANG; MIN HUANG; WEI DUAN et al.Current pharmaceutical design. 2007, Vol 13, Num 9, pp 963-978, issn 1381-6128, 16 p.Article

Protective effects of 4-nerolidylcatechol against genotoxicity induced by cyclophosphamideVALADARES, M. C; REZENDE, K. R; PEREIRA, E. R. T et al.Food and chemical toxicology. 2007, Vol 45, Num 10, pp 1975-1978, issn 0278-6915, 4 p.Article

The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in ratsAFSHARIAN, Parvaneh; TERELIUS, Ylva; HASSAN, Zuzana et al.Clinical cancer research. 2007, Vol 13, Num 14, pp 4218-4224, issn 1078-0432, 7 p.Article

The Immunoregulatory Roles of Natural Killer T Cells in Cyclophosphamide-Induced ToleranceIWAI, Toshiro; TOMITA, Yukihiro; SHIMIZU, Ichiro et al.Transplantation. 2007, Vol 84, Num 12, pp 1686-1695, issn 0041-1337, 10 p.Article

DL-α-lipoic acid ameliorates cyclophosphamide induced cardiac mitochondrial injuryMYTHILI, Y; SUDHARSAN, P. T; VARALAKSHMI, P et al.Toxicology (Amsterdam). 2005, Vol 215, Num 1-2, pp 108-114, issn 0300-483X, 7 p.Article

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthaseLOEFFLER, Markus; KRÜGER, Jörg A; REISFELD, Ralph A et al.Cancer research (Baltimore). 2005, Vol 65, Num 12, pp 5027-5030, issn 0008-5472, 4 p.Article

Schnitzler's syndrome treated successfully with intravenous pulse cyclophosphamidePETERLANA, D; PUCCETTI, A; TINAZZI, E et al.Scandinavian journal of rheumatology. 2005, Vol 34, Num 4, pp 328-330, issn 0300-9742, 3 p.Article

Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in ratsYILDIRIM, Ibrahim; KORKMAZ, Ahmet; OTER, Sukru et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 5, pp 469-473, issn 0344-5704, 5 p.Article

Influence of age upon ifosfamide-induced nephrotoxicityMCCUNE, Jeannine S; FRIEDMAN, Debra L; SCHUETZE, Scott et al.Pediatric blood & cancer. 2004, Vol 42, Num 5, pp 427-432, issn 1545-5009, 6 p.Article